AB215338

HRP Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)]

RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(8 Publications)

Rabbit Recombinant Monoclonal JAK1 phospho Y1034 + Y1035 antibody - conjugated to HRP. Suitable for Dot, WB, ELISA, IHC-P and reacts with Synthetic peptide, Human samples. Cited in 8 publications.

View Alternative Names

JAK1A, JAK1B, JAK1, Tyrosine-protein kinase JAK1, Janus kinase 1, JAK-1

2 Images

Lab

Western blot - HRP Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)] (AB215338)

All lanes:

Western blot - HRP Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)] (ab215338) at 1/1000 dilution

Lane 1:

Untreated Ramos cells

Lanes 2 - 3:

Ramos cells treated with pervanadateat at 1mM for 30min

Predicted band size: 133 kDa

Observed band size: 133 kDa

false

Exposure time: 5s

Lab

Dot Blot - HRP Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)] (AB215338)

Dot blot analysis of JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)] (HRP) (ab215338) at 1/1000 dilution.
Lane 1 : JAK1 (phospho Y1034) phospho peptide.
Lane 2 : JAK1 (phospho Y1035) phospho peptide.
Lane 3 : JAK1 (phospho Y1034 + Y1035) phospho peptide.
Lane 4 : JAK1 non phospho peptide.

Blocking and diluting buffer and concentration : 5% NFDM/TBST. Exposure time : 3 minutes.

519 Alexa Fluor® 488

Alexa Fluor® 488 Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)]
665 Alexa Fluor® 647

Alexa Fluor® 647 Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)]
603 Alexa Fluor® 568

Alexa Fluor® 568 Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)]
565 Alexa Fluor® 555

Alexa Fluor® 555 Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)]
Unconjugated

Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)]
Carrier free

Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR1899(2)

Isotype

IgG

Conjugation

HRP

Excitation/Emission

Carrier free

Reacts with

Human, Human

Applications

Dot, WB, ELISA, IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "Dot" : {"fullname" : "Dot Blot", "shortname":"Dot"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ELISA" : {"fullname" : "ELISA", "shortname":"ELISA"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "Dot-species-checked": "guaranteed", "Dot-species-dilution-info": "", "Dot-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "ELISA-species-checked": "guaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" }, "Synthetic peptide": { "Dot-species-checked": "testedAndGuaranteed", "Dot-species-dilution-info": "1/1000", "Dot-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "ELISA-species-checked": "notRecommended", "ELISA-species-dilution-info": "", "ELISA-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }

style

left-column

Product details

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.4 Preservative: 0.1% Proclin 300 Solution Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Stable for 12 months at -20°C|Store in the dark

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

JAK1 also known as Janus Kinase 1 plays an essential role in transmitting signals within cells. It is a tyrosine kinase enzyme with a molecular weight of approximately 130 kDa. JAK1 is expressed broadly in various tissues and is involved in cytokine receptor signaling. The kinase activity of JAK1 gets activated upon cytokine binding to its respective receptor which leads to phosphorylation events and downstream signaling cascades.

Biological function summary

This enzyme participates significantly in the immune response and hematopoiesis by being part of the JAK-STAT signaling pathway complex. When activated JAK1 phosphorylates specific tyrosine residues on the receptor creating docking sites for STAT proteins which then get phosphorylated by JAK1. This phosphorylation allows STAT proteins to dimerize and translocate to the nucleus affecting gene expression involved in growth survival and differentiation processes.

Pathways

JAK1 is importantly engaged in the JAK-STAT pathway and the Interferon signaling pathway. Within these pathways JAK1 collaborates closely with other proteins like JAK2 TYK2 and STAT proteins. It acts as a mediator of the cellular response to a variety of cytokines and growth factors playing a role in the regulation of immune responses and cell proliferation.

Dysregulation of JAK1 associates with autoimmune diseases like rheumatoid arthritis and certain cancers. JAK1 inhibitors have been developed as therapeutic agents for these conditions targeting its kinase activity to modulate aberrant signaling. The interaction between JAK1 and other kinases such as JAK2 and transcription factors like STATs highlights its importance in disease mechanisms providing a target for drugs to manage inflammatory and malignant disorders.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway (PubMed : 16239216, PubMed : 28111307, PubMed : 32750333, PubMed : 7615558, PubMed : 8232552). Kinase partner for the interleukin (IL)-2 receptor (PubMed : 11909529) as well as interleukin (IL)-10 receptor (PubMed : 12133952). Kinase partner for the type I interferon receptor IFNAR2 (PubMed : 16239216, PubMed : 28111307, PubMed : 32750333, PubMed : 7615558, PubMed : 8232552). In response to interferon-binding to IFNAR1-IFNAR2 heterodimer, phosphorylates and activates its binding partner IFNAR2, creating docking sites for STAT proteins (PubMed : 7759950). Directly phosphorylates STAT proteins but also activates STAT signaling through the transactivation of other JAK kinases associated with signaling receptors (PubMed : 16239216, PubMed : 32750333, PubMed : 8232552).

See full target information JAK1 phospho Y1034 + Y1035

style

left-column

Publications (8)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in pharmacology 14:1138858 PubMed37388447

2023

Network pharmacology-based approach to explore the underlying mechanism of sinomenine on sepsis-induced myocardial injury in rats.

Applications

Unspecified application

Species

Unspecified reactive species

Linggang Sun,Zhiyun Chen,Yunjie Ni,Zhengfei He

Experimental and therapeutic medicine 22:875 PubMed34194553

2021

Curcumin inhibits the viability, migration and invasion of papillary thyroid cancer cells by regulating the miR-301a-3p/STAT3 axis.

Applications

Unspecified application

Species

Unspecified reactive species

Ying Liang,Deyu Kong,Yi Zhang,Siqi Li,Yan Li,Liying Dong,Ningxin Zhang,Junfeng Ma

BioFactors (Oxford, England) 46:821-830 PubMed32141657

2020

Skullcapflavone I has a potent anti-pancreatic cancer activity by targeting miR-23a.

Applications

Unspecified application

Species

Unspecified reactive species

Jing Cui,Hao Li,Ying Wang,Tian Tian,Chao Liu,Yanan Wang,Shukai Sun,Baisui Feng

Iranian journal of basic medical sciences 22:541-546 PubMed31217935

2019

microRNA-29a functions as a tumor suppressor in nasopharyngeal carcinoma 5-8F cells through targeting VEGF.

Applications

Unspecified application

Species

Unspecified reactive species

Qingyuan Shi,Jinhua Dai,Lizhen Huang

Life sciences : PubMed31085241

2019

WITHDRAWN: Skullcapflavone I has a potent anti-pancreatic cancer activity by targeting miR-23a.

Applications

Unspecified application

Species

Unspecified reactive species

Jing Cui,Hao Li,Ying Wang,Tian Tian,Chao Liu,Yanan Wang,Shukai Sun,Baisui Feng

BMC cancer 18:1230 PubMed30526546

2018

Curcumin inhibits proliferation, migration, invasion and promotes apoptosis of retinoblastoma cell lines through modulation of miR-99a and JAK/STAT pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Yaping Li,Weixuan Sun,Ning Han,Ying Zou,Dexin Yin

Cellular physiology and biochemistry : internation 50:2188-2202 PubMed30415256

2018

Pro-Angiogenic Role of LncRNA HULC in Microvascular Endothelial Cells via Sequestrating miR-124.

Applications

Unspecified application

Species

Unspecified reactive species

Dexin Yin,Yezhou Li,Changgeng Fu,Ye Feng

Journal of cellular biochemistry 120:836-847 PubMed30125989

2018

Deletion of long noncoding RNA EFNA3 aggravates hypoxia-induced injury in PC-12 cells by upregulation of miR-101a.

Applications

Unspecified application

Species

Unspecified reactive species

Weijun Gong,Shuyan Qie,Peiling Huang,Jianing Xi

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

HRP Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)]

Western blot - HRP Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)] (AB215338)

Dot Blot - HRP Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)] (AB215338)

Related conjugates and formulations (6)

Key facts

Host species

Clonality

Clone number

Isotype

Conjugation

Excitation/Emission

Carrier free

Reacts with

Applications

Immunogen

Complementary Products

Primary Antibodies

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (8)

Product promise